Schonfeld Strategic Advisors LLC Acquires Shares of 93,134 Enfusion, Inc. (NYSE:ENFN)

Schonfeld Strategic Advisors LLC acquired a new stake in shares of Enfusion, Inc. (NYSE:ENFN) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 93,134 shares of the company’s stock, valued at approximately $959,000. Schonfeld Strategic Advisors LLC owned approximately 0.07% of Enfusion as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in the company. EVR Research LP acquired a new position in Enfusion during the 4th quarter valued at $4,120,000. New York State Common Retirement Fund lifted its holdings in Enfusion by 23.8% in the fourth quarter. New York State Common Retirement Fund now owns 1,926,968 shares of the company’s stock valued at $19,848,000 after buying an additional 370,498 shares during the period. Arrowstreet Capital Limited Partnership acquired a new position in shares of Enfusion during the 4th quarter worth about $2,358,000. Impax Asset Management Group plc boosted its position in shares of Enfusion by 31.5% during the fourth quarter. Impax Asset Management Group plc now owns 890,000 shares of the company’s stock worth $9,167,000 after purchasing an additional 213,052 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Enfusion by 612.4% in the third quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company’s stock valued at $1,974,000 after buying an additional 178,821 shares in the last quarter. Institutional investors own 81.05% of the company’s stock.

Wall Street Analyst Weigh In

Separately, William Blair reissued a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th.

Enfusion Trading Up 0.5 %

Shares of ENFN opened at $10.85 on Friday. The stock has a market capitalization of $1.40 billion, a P/E ratio of 271.29, a price-to-earnings-growth ratio of 1.85 and a beta of 0.92. Enfusion, Inc. has a 12 month low of $7.83 and a 12 month high of $11.80. The firm’s fifty day simple moving average is $10.96 and its two-hundred day simple moving average is $10.59.

Enfusion (NYSE:ENFN) last released its quarterly earnings results on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The company had revenue of $52.94 million during the quarter, compared to analysts’ expectations of $53.98 million. As a group, research analysts predict that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Oleg Movchan sold 11,452 shares of the firm’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $11.39, for a total transaction of $130,438.28. Following the completion of the transaction, the chief executive officer now directly owns 631,847 shares in the company, valued at $7,196,737.33. This trade represents a 1.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Neal Pawar sold 2,769 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $31,788.12. Following the completion of the transaction, the chief operating officer now directly owns 1,231,627 shares in the company, valued at $14,139,077.96. The trade was a 0.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 66,223 shares of company stock valued at $754,778. Corporate insiders own 36.44% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.